Scarica l'app Stockscreener
1.6894
6.92%
0.1094
Precedente Chiudi:
$1.58
Aprire:
$1.59
Volume 24 ore:
58,270
Relative Volume:
0.03
Capitalizzazione di mercato:
$5.96M
Reddito:
-
Utile/perdita netta:
$-15.47M
Rapporto P/E:
-3.3788
EPS:
-0.5
Flusso di cassa netto:
$-13.51M
1 W Prestazione:
+14.93%
1M Prestazione:
+13.92%
6M Prestazione:
-58.18%
1 anno Prestazione:
-69.39%
Intervallo 1D:
$1.59
$1.78
Intervallo di 1 settimana:
$1.41
$1.78
Portata 52W:
$1.30
$18.39
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Nome
Nls Pharmaceutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NLSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
1.6966 | 5.96M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.57 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.35 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.76 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.45 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.51 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ltd Borsa (NLSP) Ultime notizie
NLS Pharmaceutics Delays Yearly Report Filing - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
NLS Pharmaceutics Announces Board Resignation Amid Restructuring Efforts - TipRanks
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) - Aktiellt
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS (PR Newswire) - Aktiellt
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com
NLS Pharmaceutics (NLSP): Promising Preclinical Results for Mazi - GuruFocus
NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks
Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - Quantisnow
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models (PR Newswire) - Aktiellt
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - ADVFN
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
What's Going On With NLS Pharmaceutics Shares Monday? - Benzinga
NLS Pharmaceutics Secures $3 Million Financing and $25 Million Equity Facility - TipRanks
NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com
NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider
NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India
NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com Canada
NLS Pharmaceutics Announces Strategic Merger and Advances in Therapeutic Pipeline - TipRanks
NLS Pharmaceutics CEO Issues Letter to Shareholders - Quantisnow
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - ACCESS Newswire
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire
AEX-2 increases total wake duration in mouse model - BioWorld Online
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire
NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa
NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com
Can NLS Pharmaceutics' Orexin Agonist Treat More Than Just Sleep Disorders? New Data Says Yes - StockTitan
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - PR Newswire
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire
NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq
Is NLSP’s price to cash per share ratio a concern for investors? - US Post News
NLS Pharmaceutics Ltd’s Shares Reel: -37.16% Quarterly Revenue Decline Amid 6.35M Market Cap - The InvestChronicle
NLS Pharmaceutics Ltd (NLSP) Shares Rise Despite Market Challenges - The News Heater
Nls Pharmaceutics Ltd Azioni (NLSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.28%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):